PUBLICATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the NASH-HCC field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Publications
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
No.82
Nat Commun.,
“Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis” (Nat. Commun., DOI: 10.1038/s41467-023-42334-y, 2023)
VIEW ARTICLE 
No.80
Front Immunol.,
“Co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis associated with decreased adiponectin expression in amurine model” (Front. Immunol., DOI:10.3389/fimmu.,2023)
VIEW ARTICLE
No.81
Sci Rep.,
“Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced β-glucan” (Sci Rep., DOI: 10.1038/s41598-023-44330-0, 2023)
VIEW ARTICLE
No.79
Int. J. Mol. Sci.,
“Pharmacological Prevention of Ectopic Erythrophagocytosis by Cilostazol Mitigates Ferroptosis in NASH” (Int. J. Mol. Sci., DOI: 10.3390/ijms241612862.,2023)
VIEW ARTICLE
No.78
Pharmacol Res Perspect.,
“Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH)” (Pharmacol Res Perspect., DOI: 10.1002/prp2.1094., 2023)
VIEW ARTICLE
No.77
Int J Mol Sci.,
“MSC-sEV Treatment Polarizes Pro-Fibrotic M2 Macrophages without Exacerbating Liver Fibrosis in NASH” (Int J Mol Sci., DOI: 10.3390/ijms24098092., 2023)
VIEW ARTICLE